The planned analysis is a prospective cost-effectiveness (cost-utility) analysis from the
perspective of the Canadian public healthcare system, examining the costs and outcomes
(quality-adjusted life years gained) of ibrutinib-based therapy compared to a standard
therapy (bendamutine-rituximab). Collection and management of the data required for the
economic analyses (including resource utilization and outcomes) will be fully integrated into
the clinical data. Health state utilities will be derived directly from the study population.